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“Men”?Background
While perhaps self-evident to the audience reading this editorial,
it is nevertheless important to emphasise that osteoarthritis (OA) is a
major global heath care problem, forwhich there are currentlynodis-
ease modifying therapies, and existing symptomatic treatment is
modestly effective for long-term management. We therefore have
not only the privilege but the responsibility of researching a disease
with enormous individual and societal need driven by astounding
prevalence andassociateddisability,where there is greatopportunity
for discovery, innovation and clinical change. It is critical then thatwe
address questions of importance, address evidence practice gaps and
tackle areas of research priority. If we are investing research in areas
with no or limited translational and implementation potential we
should critically appraise its relevance.
In this context it is important to reﬂect on the distribution of
research funding, its waste and its focus. We are all facing uncertain
economic times and in real terms inmany countries throughout the
world, research funding is declining, and how that money should
be best expended is an increasingly important and debated issue1,2.
Arguably as a consequence of the (quite proper) desire for greater
return on investment in terms of gains for human health, the pro-
portion of government and/or charitable funding given to “basic”
rather than “clinical/health services” research has declined e.g.,
68.3% in 2004e5 to 59.4% in 2009e10 in the UK1, and 58% in
2003e4 to 45% in 2014e15 in Australia3. Whether the current trend
in distribution of funding will better translate to improved clinical
outcomes in the short and/or long term remains to be seen.
This brief introduction sets the scene for the debate question:
Should Osteoarthritis Research Focus on “Mice” or “Men”? As high-
lighted above, the topic of this debate is not unique to the OA
research community, but it afforded an opportunity for us to reﬂect
on current research in the ﬁeld and its direction. While the debate
during the OARSI World Congress in Seattle (April 30eMay 3, 2015)
was intentionally pitched to be controversial and hopefully enter-
taining, the comments in this editorial are more measured and
considered to highlight strengths and weaknesses, to promote
thought and discussion, and ultimately improvements in the qual-
ity of our research and a greater focus on translational activity. For
the purposes of the debate and this discussion, we interpreted
“mice” to mean any pre-clinical animal research, “men” to mean
research in humans, and that “research focus” implied the pathway
that would most likely provide the greatest outcome in terms of
managing and hopefully ﬁnding a cure for OA.http://dx.doi.org/10.1016/j.joca.2015.07.029
1063-4584/© 2015 Osteoarthritis Research Society International. Published by Elsevier LThe argument for “mice”
The rationale for promoting the conduct of pre-clinical (“mice”)
OA research, is perhaps best summed up by a quote from The Asso-
ciation of American Medical Colleges4; a not-for-proﬁt association
representing all 141 accredited US and 17 accredited Canadian
medical schools, nearly 400 major teaching hospitals and health
systems, including 51 Department of Veterans Affairs medical cen-
ters, and nearly 90 academic and scientiﬁc societies: “In the absence
of information and insights generated from basic research, it is difﬁcult
to envision how future advancement in treatment of disease and
disability will occur; physicians would increasingly be in the position
of mechanics who do not know how engines work, or programmers
who do not understand how computers store and compile information.
Basic research is also a source for new tools, models, and techniques
(e.g., knockout mice, functional magnetic resonance imaging, etc.)
that revolutionize research and development beyond the disciplines
that give rise to them.” This peak body representing the educators
of clinicians and the providers of patient clinical care recognises
that pre-clinical “mice” research is as described by the head of
NIH “the engine that powers tomorrow's therapeutic discoveries”5.
OA research in “man” can provide information on risk factors
and disease association. Pre-clinical research by being able to mea-
sure the effect(s) on OA disease outcome of interventions
(including genetic modiﬁcations) that may not be appropriate for
clinical use but that target speciﬁc cellular andmolecular pathways,
can much more readily distinguish “cause and effect”, and thus
identify the key mechanisms of disease initiation, onset and pro-
gression. Only with this knowledge will we deﬁne the best thera-
peutic targets of both OA pain/disability and structural disease.
Using such data from pre-clinical OA models remains the most
common path to develop new therapeutic approaches, and testing
in thesemodels optimises treatment use (e.g., timing, disease stage,
OA phenotype) to guide design of appropriate clinical trials and ul-
timately their introduction into clinical practice6. The majority of
drug development programs in Phase II and III fail because of inad-
equate clinical efﬁcacy that is attributed to insufﬁcient linkage of
the molecular/cellular target with the disease, no validated models,
and use in indications not ﬁtting the strongest pre-clinical evi-
dence7,8. Thus drug development programs fail predominantly
because their biological rationale, which is largely deﬁned by pre-
clinical research, was insufﬁcient. The reasons underlying the inad-
equacy of this “starting evidence” are manifold and include issues
with the conduct and reporting of pre-clinical research9. Howevertd. All rights reserved.
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reasons for drug development failures suggest greater emphasis
on basic research to better understand disease pathophysiology
and therapeutic target biology will improve subsequent clinical
success. In the absence of such a therapeutic development pipeline,
there will be no more new drugs for OA pain or structural disease
modiﬁcation to test in “man”. Unless as an OA-research community
we currently believe we have all the knowledge needed on OA
pathophysiology, disease targets, and treatment, or that exercise,
physical therapy, weight loss and current pharmacological and sur-
gical interventions will provide the necessary management
required to deal with the massive and growing OA problem, we
must continue to focus on “mice” (pre-clinical) research.Trial failures 
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Fig. 1. Reasons for trial failures of disease modifying drugs in OA.The argument for “man”
When conducting research into a disease as heterogeneous and
complex as OA there is no better model to study than the human
condition itself. While there are tremendous challenges within
the context of research in human OA, including those related to
deﬁning an appropriate phenotype, the discord between structural
change and symptoms, the lack of regulatory approved biomarkers
for structure modifying endpoints in clinical trials and the variation
of deﬁnitions related to long-term clinical outcomes, these are able
to be overcome.
There are a number of advantages in conducting clinical
research in humans when it is this population you ultimately
want to provide innovative interventions for. If you're interested
in the toxicity of treatments for OA in humans in the end this needs
to be tested in humans. Pre-clinical toxicity studies are usually done
in young otherwise healthy animals that do not reﬂect the pharma-
cokinetics of the aged human population with multiple co-
morbidities being treated for OA10. The majority of persons who
develop OA do so as a consequence of age-related disease within
the context of biomechanical alterations, inﬂammation and various
co-morbid conditions. A smaller proportion of persons develop dis-
ease as a consequence of a deﬁnable injury. In contrast, most animal
models of OA induce disease via mechanical disruption of joint
biomechanics in young individuals rather than the spontaneous
development of age-associated disease, let alone in association
with other risk factors (e.g., obesity, menopause)11. Whilst the fail-
ure to translate most OA pre-clinical research into something with
clinical impact is multi-factorial (Fig. 1) this latter point is critical.
Studies in genetically modiﬁed mice suggest that post-traumatic
(PT)OA can have a distinct molecular pathophysiology compared
with that of spontaneous OA, which likely contributes to the poor
translation from preclinical to clinical OA therapeutic trials11.
Approximately 80e85 million years ago, we (humans) took a
different evolutionary path to mice. We are bipeds as opposed to
quadrupeds, our joint biomechanics and anatomy is distinct,
including for example vast differences in the thickness of cartilage
compared with species used in pre-clinical research, that likely has
important implications for therapeutic development12. Similarly
during evolution the human brain underwent extraordinary devel-
opment, and along with that the arguably unique perception of
self and complex cognitive capabilities and social interactions.
This higher intellectual development in humans has signiﬁcant
implications with regard to the perception of and response to
chronic pain and physical disability. How well the human bio-
psychosocial model of pain can be mimicked in pre-clinical models
is debated, and provides a potentially major source of translational
research and drug development failure13,14. Given that pain and
disability are the major clinical symptoms of OA that require med-
ical management, lack of adequate modelling of these in “mice”provides one of the strongest arguments for focusing OA research
on “man”.What's wrong with the current OA research paradigm?
Global biomedical and public health research involves billions of
dollars and millions of people15. While this extraordinary
endeavour has clearly improved health delivery and outcomes, it
has been suggested that “many more gains are possible if the waste
and inefﬁciency in the ways that biomedical research is chosen,
designed, done, analysed, regulated, managed, disseminated, and re-
ported can be addressed”15. In 2009, Chalmers and Glasziou16 esti-
mated that the cumulative effect was that about 85% of
biomedical research investmentdequating to $200 billion of the
investment in 2010dis wasted. These authors suggested four
main areas in which biomedical research in general is wasteful:
(1) choosing the wrong question to research, (2) doing studies
that are unnecessary or poorly designed, (3) failing to publish the
research, and (4) when it is reported the data provided is inade-
quate, biased or unusable (Fig. 2). A series of papers have reviewed
and highlighted concerns over the poor quality and reproducibility
of both preclinical (“mice”) and clinical (“man”) biomedical
research17e23. It would be naïve to think that these issues do not
apply to OA research, and unless the quality, rigour and reproduc-
ibility of our research improves, challenges with its translation to
real beneﬁts for patients will continue.
It is increasingly recognised that biomedical research funding is
poorly correlated with the relative burden of disease16. Recent esti-
mates suggest that 250 million people worldwide are burdened by
the presence of knee OA24. According to the Global Burden of Disease
(GBD) Study 2010 OA accounted for 0.6% of all disability-adjusted life
year (DALYs) and 10.0% of DALYS due to musculoskeletal conditions.
This burden explains 2.2% of global years lived lost due to disability
(YLD) and 10% of all YLD from musculoskeletal disorders25,26. As a
group, musculoskeletal disorders cause 21.3% of all years lived with
disability, second only to mental and behavioural disorders. The
cost of OA in most western countries has been estimated to account
for between 1% and 2.5% of the gross national product27. Despite the
signiﬁcant and growing burden of OA and the pressing need to
Fig. 2. Stages of waste in the production and reporting of biomedical research evidence relevant to clinicians and patient.
Reprinted with permission from Chalmers I and Glasziou P. Lancet 2009; 374: 86e89, Copyright (2009), with permission from Elsevier.
Editorial / Osteoarthritis and Cartilage 24 (2016) 4e86improve its treatment and management, OA research is poorly
funded. Australian (NHMRC) funding for OA research was only $8.2
million in 201428, or less than 0.21% of the direct health system costs
(~$4 billion29) ofmanaging the disease. This level of research funding
is substantially lower than for other comparable chronic conditions;
funding for diabetes research for example, was $70million in 2012 or
5.6% of the health system costs (~$1.1 billion30) of the condition31.
Clearly we would argue that a greater % of available health care
research $ should be directed towards OA.How can we improve OA research?
Although our understanding of biological mechanisms in OA has
increased dramatically in the last decade, translation of this funda-
mental knowledge to improved clinical practice remains unsatisfac-
tory. There will never be enough funding and it is important that we
prioritize its use and optimize the potential outcomes. To attract and
use research funding wisely our research, both “mice and man”,
needs to face and then address shortcomings in the “waste areas”
identiﬁed by Chalmers and Glasziou16. A clear ﬁrst step is to ensure
OA research is addressing questions of relevance to clinicians and pa-
tients, and measures to identify these priorities have been taken in a
number of countries32e34. As in all biomedical ﬁelds, having deﬁned
the key questions, efforts must be made to improve the design,
conduct, analysis and reporting of OA research at all levels from
“mice to men”1,15,19,35,36. We have particular issues in OA research,
related to the insidious onset of disease prior to clinical symptoms,
prolonged time course for progression, and poor phenotype deﬁni-
tions. These clinical realities mean we must strive to solve existing
problems with the predictive utility of pre-clinical models, the lack
of biomarkers for structure modifying endpoints in clinical trials,
and the variation of deﬁnitions for long-term clinical outcomes.
We argue that greater focus needs to be given to improving trans-
lational value of research. That said, for translational research to be
fully effective, we need more than just funding, we need cultural
change37. The latter includes: (1) removing silos (such as those be-
tween basic and clinical researchers; research institutes, universitiesand health care providers/hospitals; academia and industry); (2)
developing appropriate ways to evaluate and reward translational
researchers and institutions (beyond typical academic KPIs of grant
dollars, publication numbers and impact factors, h-index, to include
milestones that might better measure potential improvement in hu-
man health such as research licenced by industry, diagnostics/drugs/
devices taken to market, health policies or programs delivered); (3)
re-imagining and re-deﬁning the relationship and collaboration be-
tween academia and industry (beyond researcher-initiated studies
toward real partnerships in therapeutic discovery and develop-
ment); (4) building tailored programs to develop and grow transla-
tional researchers (that embrace the “bed-to-bench-to-bed”
paradigm and provide training in issues and researchmethods perti-
nent to industry as well as academia); and (5) reducing waste while
at the same time ensuring that investigator-driven research is not
lost, and more money and time are not spent in meeting research
regulations while direct programmatic dollars are declining. We
are in the privileged position of researching an incredibly prevalent
disabling disease with opportunities for tremendous advance: we
should not abuse that privilege and waste our precious research re-
sources and rather focus more on improving all the research that we
do. There is a vast array of diverse talent within our ﬁeld and
together we can make a difference.
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